New Study: Extracellular Vesicles in Fibrin Gel for Cartilage Repair (Italy)
The Italian researchers will do a 51 person trial with MSC-derived EVs in PRP-derived fibrin gels.
Category: Trials
New Study: Intrathecal Umbilical Stem Cells + Transcutaneous Stimulation for Spinal Cord Injury
The neurorehabilitation hospital in Spain will investigate if allogeneic umbilical-derived stem cell therapy can help enhance recovery.
Hematopoietic Stem Cell-Directed Gene Insertion Therapy Gets IND Clearance
With FDA clearance secured, Ensoma prepares to launch its Phase 1/2 clinical trial to establish safety, efficacy, and dosing.
Safety and Efficacy of Epicardial Implantation of Collagen Membranes with Allogeneic Adipose-Derived Stem Cells (Cardiomesh)
This study will evaluate if the VB-C01 cellularised patch, a collagen membrane seeded with allogeneic adipose-derived stem cells, is safe and effective for surgical epicardial implantation in patients undergoing coronary artery bypass...
iPSC-Derived Motor Neuron Cells’ Dose Escalation Trial for Subacute Spinal Cord Injury, a Phase I
This study will evaluate if allogeneic human induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cells (XS228, made by XellSmart) can safely and effectively treat subacute spinal cord injury. Researchers at the...
ALS Stem Cell Trial: Efficacy and Safety of NurOwn in Early & Moderate ALS (ENDURANCE STUDY)
Brainstorm Therapeutics is back, and they've learned a lot from their previous trials. If you don't know the history of Nurown, their ALS stem cell candidate, it showed early promise in Phase...
Korean Company Launches iPSCs Osteoarthritis Trial
Biotech company YiPSCELL breaks ground on a new trial, will head to safety & efficacy trials soon.
Stem cell trial for early Alzheimer’s disease to begin at UTHealth Houston, will use Hope Biosciences’ technology
Will adipose stem cell therapy hold an answer for neuroinflammation, a factor in Alzheimer's?
Phase III Stem Cell Trial for Epilepsy Launching This Year from Neurona Therapeutics
This follows their RMAT designation, and promising Phase 1/2 trial results, which they presented earlier this year.
Off-the-shelf stem cells for heart failure: Trial reports positive results, independent board recommends moving forward with using BioCardia’s CardiALLO
BioCardia plans to move forward with enrollment of up to 39 participants in the United States.
